Streetwise Reports' Article Archives — July 2026 back to current month (44)
Biotech Produces Ebola Proteins in Just 15 Days as African Outbreak Intensifies (07/31/2026)
Dyadic International Inc. (NASDAQ: DYAI) has rapidly developed and produced recombinant protein antigens targeting Bundibugyo ebolavirus, progressing from receipt of the plasmids to purified proteins in approximately 15 days. As the Ebola outbreak in Africa continues, this achievement highlights the speed and potential of Dyadics C1 protein-production platform. Read why one technical analyst believes DYAIs' stock could be positioned for a bullish move.
Dyadic C1 Platform Delivers Ebola Antigens in 15 Days (07/31/2026)
Dyadic International produced two Bundibugyo ebolavirus antigens in about 15 days using its C1 platform and delivered them for preclinical testing amid an active outbreak in Africa.
Wet AMD Drug Secures First FDA-Approved Bevacizumab Status (07/30/2026)
Outlook Therapeutics gains FDA approval for LYTENAVA, the first ophthalmic bevacizumab for wet AMD. The approval opens access to an $8.5 billion U.S. market with 12 years of exclusivity expected.
Blood in the Streets: Why I'm Buying Gold Miners, a Peru Tailings Giant, and Two Biotech 10-Baggers This Summer (07/30/2026)
Newsletter writer Chen Lin shares his view on the current state of the market and shares some stocks on his list.
Smith & Nephew Expands Wound Care Portfolio in $22B Market (07/29/2026)
Smith & Nephew advances chronic wound solutions as the global market grows to $30.48B by 2030. Learn about new products, revenue trends, and investor considerations.
FDA Approves First Ophthalmic Treatment for Wet AMD, Leading Wainwright to Triple Price Target (07/29/2026)
Outlook Therapeutics Inc.'s (OTLK:NASDAQ) LYTENAVA received FDA approval as the first ophthalmic bevacizumab for wet AMD, with U.S. launch targeted by year-end 2026
Biotech's Non-Cytotoxic Copper-Iodine Wound Platform Shows 72-Hour Antimicrobial Persistence in Lab Testing (07/29/2026)
As an aging population expands demand in the wound care market, a smaller player is taking on the one of the most established with its "chemistry-on-demand" technology.
Scancell, Neuphoria Agree to All-Share Merger (07/29/2026)
Neuphoria Therapeutics Inc. (NEUP:NASDAQ) and Scancell Holdings Plc (SCNLF:OTC; SCLP:AIM) agreed to an all-share merger, listing the combined company on Nasdaq while funding a Phase 3 melanoma trial.
Melanoma Biotech Secures Nasdaq Listing via All-Share Merger (07/29/2026)
Scancell advances its iSCIB1+ melanoma program toward Phase 3 after agreeing to an all-share merger that brings Nasdaq access and up to $89 million in new financing.
Novocure Posts Record Q2 Revenue of US$183.6M (07/27/2026)
Novocure Ltd. (NVCR:NASDAQ) posted record Q2 2026 revenue of US$183.6 million, up 16% year-over-year, and raised full-year guidance to US$710-US$725 million.
Novocure Hits Record Revenue and Raises 2026 Outlook (07/27/2026)
Novocure posts record Q2 revenue of $183.6 million and lifts full-year guidance after Optune Pax earns CE Mark approval in Europe. See the key catalysts for investors.
US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead (07/24/2026)
A full FDA clinical hold covers all studies of this hyperphagia candidate, and the company plans to unblind Phase 3 data. An analyst warned the trial "may need to be repeated in its entirety."
PolyPid, Azurity Sign US$330M Deal for D-PLEX100 (07/23/2026)
PolyPid Ltd. (PYPD:NASDAQ) and Azurity Pharmaceuticals signed a deal worth up to US$330 million to commercialize D-PLEX100, an infection-prevention drug, in the U.S. and Canada.
Antibacterial Drug Partnership Accelerates PolyPid Commercial Path (07/23/2026)
PolyPid enters a major commercialization deal with Azurity for D-PLEX100 targeting surgical site infections, with upfront payments and milestone potential supporting retail investors watching PYPD progress toward 2027 launch.
Biotech Advances VOXZOGO Toward Landmark US FDA Approval (07/20/2026)
BioMarin Pharmaceuticals Inc.'s (BMRN:NASDAQ) supplemental New Drug Application seeking traditional approval for VOXZOGO (vosoritide) to treat children with the genetic bone-growth disorder achondroplasia has been accepted.
BioMarin Advances VOXZOGO Toward Full FDA Approval (07/20/2026)
BioMarin submits sNDA for traditional VOXZOGO approval in achondroplasia with a Feb 2027 PDUFA date backed by extensive long-term data and an expanding skeletal dysplasia market opportunity.
Healthcare Platform Clears Major Security Milestone After Independent Audit (07/17/2026)
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) said its wholly owned Rocket Doctor platform achieved SOC 2 Type I compliance following an independent third-party audit of its security, privacy, and operational controls.
Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale (07/17/2026)
Summit Therapeutics Inc. (SMMT:NASDAQ; SUMM:LON) is selling its Phase 3 antibiotic to Biossil for up to US$104.5 million in milestones, refocusing on its oncology drug ivonescimab.
Summit Therapeutics Pivots to Ivonescimab Amid Oncology Boom (07/17/2026)
Summit Therapeutics shifts focus to ivonescimab in the expanding oncology sector. Learn about its pipeline catalysts, analyst views, and key investor considerations for this cancer-focused biopharma.
Digital Health Platform Achieves SOC 2 Milestone in Booming Sector (07/17/2026)
Rocket Doctor AI reaches SOC 2 Type I compliance, strengthening its enterprise position as the digital health market expands rapidly with rising AI adoption.
Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target (07/16/2026)
Roth, Chardan Capital, and H.C. Wainwright have all issued "Buy" ratings on Coya Therapeutics Inc. (COYA:NASDAQ) in 2026. Read on to find out why analysts are intrigued.
Houston ALS Biotech Coya Eyes 2028 Approval Path (07/16/2026)
Coya Therapeutics advances COYA 302 for ALS with strong analyst support and a key 2027 readout ahead. Discover the catalysts and industry trends driving this Houston biotech.
Cleantech Co. Relaunches Pet Brand Under Its Own Control (07/15/2026)
BioLargo Inc. (BLGO:OTCQX) unveils plans to reintroduce its enormously popular CupriDyne-based pet odor products to the consumer market. This time, the company says it will own the brand and do it its own way.
AI Engine Delivers Engagement Gains as Recurring Revenue Outlook Climbs (07/15/2026)
DarioHealth Corp. (DRIO:NASDAQ) said its DarioIQ platform reflects the ongoing digital health rotation and AI transformation across healthcare, with broader deployment expected to increase recurring revenue from existing customers by 10% to 15%.
Pet Odor Market Ignites BioLargo Consumer Comeback (07/15/2026)
BioLargo re-enters the booming U.S. pet odor control market with a direct-to-consumer CupriDyne brand, building on proven demand while advancing water treatment and medical technologies for retail investors.
DarioHealth AI Platform Targets 10-15% Revenue Growth from Existing Clients (07/15/2026)
DarioHealth's DarioIQ AI engine is positioned to lift B2B2C recurring revenue 10-15% from current customers while the AI healthcare market expands rapidly toward hundreds of billions.
Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation (07/14/2026)
Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win (07/10/2026)
Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity.
Biotech With Muscle Disease Drug Uncovers Results in Trial Data (07/09/2026)
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.
NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss (07/08/2026)
The FDA accepted the company's morpholino oligomer filings with a February 2027 PDUFA date, but a missed confirmatory trial endpoint clouds its path to full approval.
Digital Health Platform Lands Access to Hundreds of Thousands of Covered Lives (07/08/2026)
DarioHealth Corp. (DRIO:NASDAQ) signed a new agreement through its Amwell partnership that makes its cardiometabolic platform available to a major Arizona health insurer's ASO business, representing hundreds of thousands of covered lives.
Air Force Bases Renew Their Contracts With Cleantech Pioneer (07/07/2026)
Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) says its engineering division has secured contract renewals worth over US$1.4 million. Find out why experts like this technology incubator's structure.
First-of-Its-Kind US Brain Imaging Clinic Takes Delivery of Key PET Scanner (07/07/2026)
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) received its first brain-dedicated PET scanning system for its flagship Florida NovaScan Neuroimaging Clinic, which the company said will be the first U.S. facility dedicated to brain-only PET imaging for Alzheimer's disease and other neurological conditions.
BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew (07/07/2026)
BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.
Grey Matters Health Inc. Targets Alzheimer's PET Imaging Opportunity (07/07/2026)
Grey Matters Health Inc. advances first U.S. brain-dedicated PET clinic for Alzheimer's detection amid surging diagnostics demand. Learn the key facts for investors.
How Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases? (07/06/2026)
Find out what analysts think of clinical-stage biotech Abivax SA (ABVX:NASDAQ), which is focusing on harnessing the immune response in patients with chronic inflammatory diseases.
Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst (07/06/2026)
Abivax SA (ABVX) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late 2026. Learn why this oral miR-124 therapy stands out for investors now.
A Wedbush analyst raised its target on a French biopharma's ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn's readout.
Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market (07/02/2026)
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) earns FDA Fast Track designation for its Duchenne treatment SAT-3247, positioning the company for potential breakthrough gains.
Abivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunity (07/02/2026)
Abivax SA (ABVX:NASDAQ) reports strong obefazimod maintenance results in ulcerative colitis. Explore sector growth, analyst targets, catalysts, and what it means for investors.
Satellos Bioscience Fast Track Win Fuels DMD Hopes (07/02/2026)
Satellos Bioscience earns FDA Fast Track for SAT-3247 in Duchenne. Explore the market opportunity, clinical catalysts, analyst targets, and what retail investors should know now.
Digital Health Pioneer Targets Massive Breakthrough Chronic Care Market (07/01/2026)
AI-driven digital health solutions pioneer DarioHealth Corp. (DRIO:NASDAQ) announces a partnership that it says will give it access to a network spanning all 50 states. Find out why analysts like the direction the company is taking.
DarioHealth (DRIO) Expands Reach via Beluga Health Deal (07/01/2026)
DarioHealth (DRIO) integrates its AI platform with Beluga Health's network to scale provider-backed care. Discover growth catalysts, analyst targets, and investor considerations.
Clinical-Stage Biotech Discloses Colitis Retreatment Results, Gets Mixed Ratings (07/01/2026)
Abivax SA (ABVX:NASDAQ) reports 69.7% clinical response and 45.0% remission rates in relapsed UC patients retreated with obefazimod in Phase 3 trial.
More Archives
2026Aug Jul Jun May Apr Mar Feb Jan
2025Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
